R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

The use of non‐pegylated liposomal doxorubicin (Myocet(®)) in diffuse large B‐cell lymphoma (DLBCL) has been investigated in retrospective and single‐arm prospective studies. This was a prospective phase 2 trial of DLBCL patients ≥60 years old with left ventricular ejection fraction (LVEF) ≥55% rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Sancho, Juan‐Manuel, Fernández‐Alvarez, Rubén, Gual‐Capllonch, Francisco, González‐García, Esther, Grande, Carlos, Gutiérrez, Norma, Peñarrubia, María‐Jesús, Batlle‐López, Ana, González‐Barca, Eva, Guinea, José‐María, Gimeno, Eva, Peñalver, Francisco‐Javier, Fuertes, Miguel, Bastos, Mariana, Hernández‐Rivas, José‐Ángel, Moraleda, José‐María, García, Olga, Sorigué, Marc, Martin, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926012/
https://www.ncbi.nlm.nih.gov/pubmed/33492774
http://dx.doi.org/10.1002/cam4.3730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926012/
https://www.ncbi.nlm.nih.gov/pubmed/33492774
http://dx.doi.org/10.1002/cam4.3730

Ejemplares similares